Amicus Therapeutics, Inc. (NASDAQ:FOLD) CFO Daphne Quimi sold 15,000 shares of the business’s stock in a transaction dated Thursday, January 9th. The stock was sold at an average price of $9.93, for a total transaction of $148,950.00. Following the transaction, the chief financial officer now owns 166,969 shares in the company, valued at $1,658,002.17. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
FOLD traded down $0.21 on Friday, reaching $9.46. The company had a trading volume of 2,729,173 shares, compared to its average volume of 3,317,054. Amicus Therapeutics, Inc. has a fifty-two week low of $7.11 and a fifty-two week high of $14.61. The stock has a market cap of $2.41 billion, a P/E ratio of -7.11 and a beta of 1.55. The company’s fifty day moving average is $9.86 and its 200 day moving average is $10.08. The company has a debt-to-equity ratio of 0.36, a quick ratio of 6.10 and a current ratio of 6.20.
Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Monday, November 11th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.08. Amicus Therapeutics had a negative net margin of 216.02% and a negative return on equity of 62.61%. The business had revenue of $48.80 million for the quarter, compared to analyst estimates of $48.05 million. During the same quarter in the prior year, the business earned ($0.84) EPS. Amicus Therapeutics’s quarterly revenue was up 136.9% on a year-over-year basis. On average, sell-side analysts expect that Amicus Therapeutics, Inc. will post -1.24 EPS for the current year.
FOLD has been the topic of several recent analyst reports. Robert W. Baird restated a “buy” rating and set a $20.00 price objective on shares of Amicus Therapeutics in a research note on Thursday. ValuEngine upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday. Cowen set a $31.00 price target on shares of Amicus Therapeutics and gave the company a “buy” rating in a research note on Thursday, October 10th. BidaskClub lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 31st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Amicus Therapeutics in a research note on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $17.96.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.
Further Reading: Guidelines for Successful Channel Trading
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.